SECuRE update: recruitment target of the Cohort Expansion Main Group achieved
Sydney, Australia 8 October 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the recruitment target of the Cohort Expansion (Main Group) of the Phase I/IIa SECuRE trial has been achieved. The…